{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:08:30Z","timestamp":1789823310123,"version":"4.0.1"},"reference-count":89,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T00:00:00Z","timestamp":1710806400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>The article reviews the safety and efficacy of treatments for cytomegalovirus (CMV) in solid organ transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature review was conducted in PubMed, MEDLINE, and Clinicaltrials.gov from database inception through January 2024, using terms CMV, therapy, and solid organ transplantation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>Clinical trials, meta-analyses, cohort studies, case reports, and guidelines were included. Letters to the editor, reviews, and commentaries were excluded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>After abstract screening and full-text review of 728 citations for eligibility, 53 were included. Valganciclovir and intravenous ganciclovir are drugs of choice for CMV management and, until recently, the availability of alternative options has been restricted due to toxicity. For instance, foscarnet and cidofovir serve as second-line agents due to potential bone marrow and renal toxicity. In patients with refractory or resistant CMV, maribavir, a novel oral agent, has proven efficacy and a lower adverse effect profile. However, in refractory or resistant CMV, foscarnet and cidofovir are preferred in invasive disease (CMV gastritis, CMV retinitis, and CMV encephalitis), high viral loads, and inability to tolerate oral preparations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Relevance to Patient Care and Clinical Practice:<\/jats:title>\n                    <jats:p>Consensus guidelines have not been revised since approval of novel antivirals in solid organ transplantation. Valganciclovir and ganciclovir remain drugs of choice for initial CMV therapy. Foscarnet, cidofovir, and maribavir are treatments for refractory or resistant-CMV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Selection of CMV antiviral treatment should be determined by patient-specific factors, including severity of illness, resistant or refractory disease, dose-limiting adverse effects, and the preferred route of administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280241237534","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T08:57:54Z","timestamp":1710838674000},"page":"1122-1133","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Cytomegalovirus Treatment in Solid Organ Transplantation: An Update on Current Approaches"],"prefix":"10.1177","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6850-7383","authenticated-orcid":false,"given":"Karen L.","family":"Hardinger","sequence":"first","affiliation":[{"name":"Division of Pharmacy Practice and Administration, School of Pharmacy, University of Missouri\u2013Kansas City, Kansas City, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Brennan","sequence":"additional","affiliation":[{"name":"Johns Hopkins Comprehensive Transplant Center, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,3,19]]},"reference":[{"key":"bibr1-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13512"},{"key":"bibr2-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000002191"},{"key":"bibr3-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199201000-00013"},{"key":"bibr4-10600280241237534","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2023.11785"},{"key":"bibr5-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000004855"},{"key":"bibr6-10600280241237534","unstructured":"Valcyte\n                      . Genentech USA, Inc.; 2021."},{"key":"bibr7-10600280241237534","unstructured":"Ganciclovir\n                      . Exela Pharma Sciences; 2017."},{"key":"bibr8-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad087"},{"key":"bibr9-10600280241237534","unstructured":"National Institute for Occupational Safety and Health (NIOSH). NIOSH list of antineoplastic and other hazardous drugs in healthcare settings, 2016. By Connor TH, MacKenzie BA, DeBord DG, Trout DB, O\u2019Callaghan JP. Publication Number 2016-161 (Supersedes 2014-138). National Institute for Occupational Safety and Health, Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. 2016. Accessed February 28, 2024. https:\/\/www.cdc.gov\/niosh\/docs\/2016-161\/pdfs\/2016-161.pdf"},{"key":"bibr10-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2007.01910.x"},{"key":"bibr11-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1086\/342601"},{"key":"bibr12-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1086\/315242"},{"key":"bibr13-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02617.x"},{"key":"bibr14-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa537"},{"key":"bibr15-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2007.00249.x"},{"key":"bibr16-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31828555ac"},{"key":"bibr17-10600280241237534","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2023.11295"},{"key":"bibr18-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02861"},{"key":"bibr19-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001338"},{"key":"bibr20-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000000386"},{"key":"bibr21-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix696"},{"key":"bibr22-10600280241237534","unstructured":"Foscavir\n                      . Hospira, Inc.; 2020."},{"key":"bibr23-10600280241237534","doi-asserted-by":"publisher","DOI":"10.3109\/inf.1985.17.issue-2.06"},{"key":"bibr24-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12852"},{"key":"bibr25-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001418"},{"key":"bibr26-10600280241237534","unstructured":"Vistide\n                      . Gilead Sciences, Inc.; 2000."},{"key":"bibr27-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70118-9"},{"key":"bibr28-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2007.00761.x"},{"key":"bibr29-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2001.13.1.100"},{"key":"bibr30-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13521"},{"key":"bibr31-10600280241237534","unstructured":"Gammagard\n                      . Takeda Pharmaceuticals U.S.A., Inc; 2024."},{"key":"bibr32-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1177\/1060028019880300"},{"key":"bibr33-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000359"},{"key":"bibr34-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2047"},{"key":"bibr35-10600280241237534","unstructured":"Cytogam\n                      . Saol Therapeutics, Inc.; 2020."},{"key":"bibr36-10600280241237534","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-109-10-783"},{"key":"bibr37-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1592\/phco.30.6.554"},{"key":"bibr38-10600280241237534","first-page":"3560","volume":"21","author":"D\u2019Alessandro AM","year":"1989","journal-title":"Transplant Proc"},{"key":"bibr39-10600280241237534","first-page":"22","volume":"25","author":"George MJ","year":"1993","journal-title":"Transplant Proc"},{"key":"bibr40-10600280241237534","first-page":"271","volume":"20","author":"Brown CB","year":"1983","journal-title":"Proc Eur Dial Transplant Assoc"},{"key":"bibr41-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13655"},{"key":"bibr42-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0000000000001097"},{"key":"bibr43-10600280241237534","doi-asserted-by":"publisher","DOI":"10.3389\/ti.2022.10332"},{"key":"bibr44-10600280241237534","unstructured":"Prevymis\n                      . Merck & Co., Inc.; 2023."},{"key":"bibr45-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706640"},{"key":"bibr46-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.9106"},{"key":"bibr47-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13166"},{"key":"bibr48-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13515"},{"key":"bibr49-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/tid.12965"},{"key":"bibr50-10600280241237534","doi-asserted-by":"publisher","DOI":"10.12890\/2020_001622"},{"key":"bibr51-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15135"},{"key":"bibr52-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01630-23"},{"key":"bibr53-10600280241237534","unstructured":"ClinicalTrials.gov. Letermovir treatment for refractory or resistant cytomegalovirus infection. Accessed January 11, 2024. https:\/\/clinicaltrials.gov\/study\/NCT03728426"},{"key":"bibr54-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-022-00746-1"},{"key":"bibr55-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.15142"},{"key":"bibr56-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13687"},{"key":"bibr57-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01623-15"},{"key":"bibr58-10600280241237534","unstructured":"Livtencity\n                      . Takeda Pharmaceuticals America, Inc.; 2023."},{"key":"bibr59-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab988"},{"key":"bibr60-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02768.x"},{"key":"bibr61-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.8.2365-2372.2002"},{"key":"bibr62-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2006.07.010"},{"key":"bibr63-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa462"},{"key":"bibr64-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-11-121558"},{"key":"bibr65-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(11)70024-X"},{"key":"bibr66-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2012.04231.x"},{"key":"bibr67-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.14929"},{"key":"bibr68-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac686ctr.14929"},{"key":"bibr69-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-3062.2010.00550.x"},{"key":"bibr70-10600280241237534","unstructured":"ClinicalTrials.gov. A study of maribavir in Japanese people with cytomegalovirus (CMV) infection. Accessed January 11, 2024. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT05137717?cond=maribavir&draw=2"},{"key":"bibr71-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13931"},{"key":"bibr72-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2010.03114.x"},{"key":"bibr73-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3182708e56"},{"key":"bibr74-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-014-0783-1"},{"key":"bibr75-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e31824810e6"},{"key":"bibr76-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-0012.2007.00699.x"},{"key":"bibr77-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-2277.2012.01489.x"},{"key":"bibr78-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2018.07.013"},{"key":"bibr79-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1172\/JCI165476"},{"key":"bibr80-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2009.02672.x"},{"key":"bibr81-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2015.12.031"},{"key":"bibr82-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.13023"},{"key":"bibr83-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2015.5"},{"key":"bibr84-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy549"},{"key":"bibr85-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)60136-0"},{"key":"bibr86-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.14925"},{"key":"bibr87-10600280241237534","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy, safety, and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in healthy participants 16 to 40 years of age. Accessed January 11, 2024. https:\/\/clinicaltrials.gov\/study\/NCT05085366"},{"key":"bibr88-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303688"},{"key":"bibr89-10600280241237534","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13733"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241237534","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280241237534","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280241237534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:13:37Z","timestamp":1777374817000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280241237534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,19]]},"references-count":89,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1177\/10600280241237534"],"URL":"https:\/\/doi.org\/10.1177\/10600280241237534","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,19]]}}}